News & Publications

KemPharm® is a clinical stage, specialty pharmaceutical company engaged in the development and discovery of proprietary prodrugs that are designed to be improved versions of widely prescribed and FDA approved products.

  • 20

    Sep

    19

  • KemPharm Provides Updates Regarding its Board of Directors

  • 17

    Sep

    19

  • KemPharm to Participate in the Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Diseases

  • 05

    Sep

    19

  • KemPharm to Present at the 21st Annual Global Investment Conference, Sponsored By H.C. Wainwright & Co.

  • 04

    Sep

    19

  • KemPharm Announces Entry into Definitive Collaboration and License Agreement for its ADHD Candidates, KP415 and KP484, with an Affiliate of Gurnet Point Capital

  • 13

    Aug

    19

  • KemPharm Reports Second Quarter 2019 Results

  • 14

    May

    19

  • KemPharm Reports First Quarter 2019 Results

  • 11

    Apr

    19

  • KemPharm Completes KP415 Pre-NDA Meeting with FDA

  • 13

    Mar

    19

  • KemPharm Provides Update on APADAZ® Formulary Adoption

  • 05

    Mar

    19

  • KemPharm to Present at Upcoming Investor Conferences

  • 28

    Feb

    19

  • KemPharm Reports Q4 and FY 2018 Results

  • 21

    Feb

    19

  • KemPharm to Report Fourth Quarter and Year End 2018 Results

  • 29

    Jan

    19

  • KemPharm Announces Enhancements to U.S. and Global Intellectual Property Estate